Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.
Atlanta, Georgia, United States The leading representative office of defined VC is situated in the Atlanta. The venture was found in North America in United States. BrightEdge Fund appeared to be a CVC structure as part of the corporation.
The typical case for the fund is to invest in rounds with 6-7 participants. Despite the BrightEdge Fund, startups are often financed by Lilly Asia Ventures, Founders Fund, Data Collective DCVC. The meaningful sponsors for the fund in investment in the same round are Andreessen Horowitz, Westlake Village BioPartners, Verily.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Personal Health, Health Care. The fund has no exact preference in some founders of portfolio startups. If startup sums 2 or 5+ of the founder, the chance for it to be financed is low. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Freenome, Navigating Cancer, Castle Biosciences.
Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. The top amount of exits for fund were in 2019. The usual things for fund are deals in the range of 50 - 100 millions dollars. The top activity for fund was in 2019. The fund is constantly included in 2-6 deals per year. Comparing to the other companies, this BrightEdge Fund performs on 4 percentage points more the average number of lead investments.
Related Funds
Funds with similar focus
| Fund Name | Location |
| China Development Bank International Investment | China, Hong Kong, Hong Kong Island |
| Concord Venture Capital Group | Taipei, Taiwan |
| Deep Track Capital | Connecticut, Greenwich, United States |
| DSM | Heerlen, Limburg, The Netherlands |
| Eqvitec | Finland, Helsinki, Southern Finland |
| First Ally Capital | - |
| Fisher Capital | Colorado, Englewood, United States |
| Ground Squirrel Ventures | Boston, Massachusetts, United States |
| Le Comptoir de l'Innovation | France, Ile-de-France, Paris |
| Mahindra Rise | India, Maharashtra, Mumbai |
| Manfeng Asset | China, Shanghai |
| Mobius Corporate Venture Capital | Community of Madrid, Madrid, Spain |
| NGK SPARK PLUG CO | Aichi Prefecture, Japan, Nagoya |
| Qingdao Fund of Venture Capital Funds | - |
| Shengjin Venture Capital | Changning, China, Shanghai |
| Starting Line | Chicago, Illinois, United States |
| Techweek | Chicago, Illinois, United States |
| Three Gorges Xintai Fund | Beijing, Beijing, China |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Thatch | $400K | 15 Feb 2023 | - | ||
Paradigm | $203M | 25 Jan 2023 | New York, New York, United States | ||
Alpheus Medical | $14M | 10 Nov 2022 | Oakdale, Pennsylvania, United States | ||
Vincere Health | $1M | 05 Oct 2022 | Boston, Massachusetts, United States | ||
Meliora Therapeutics | $11M | 29 Sep 2022 | San Francisco, California, United States | ||
Naveris | $33M | 19 Sep 2022 | Massachusetts, United States | ||
Auron Therapeutics | $48M | 20 Jul 2022 | Massachusetts, United States | ||
Persephone Biosciences | $15M | 19 Jul 2022 | San Diego, California, United States | ||
CellCentric | 26 Jan 2022 | Cambridge, England, United Kingdom |
– Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing.
– The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society . Existing investors Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor Longwood Fund also joined the round.
– The company intends to use the funds to advance its lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data 
Get matched with relevant funds
